|
|
Post by sla55 on Jan 8, 2015 17:53:07 GMT -5
|
|
|
|
Post by savzak on Jan 8, 2015 17:55:07 GMT -5
FEATURED SPEAKER 11:05 Dry Powder Formulations for the Inhalation of Oxyntomodulin leone bay andrea drug discovery Andrea Leone-Bay Vice President Scientific Research MannKind Obesity is a rapidly becoming a global epidemic and underlies many disease conditions including diabetes and cardiovascular disease. Current treatment options are limited and are challenged by undesirable side effects. Oxyntomodulin (OXY) is an endogenous peptide hormone that signals satiety in healthy individuals. High circulating OXY concentrations are associated with satiety and low OXY concentrations are associated with a feeling of hunger. This activity profile positions OXY as a potential treatment for obesity. To address this unmet medical need, this presentation will introduce an approach to developing an orally inhaled dry powder OXY product administered using a small, breath-powered inhaler for obesity therapy. The audience will learn about oxyntomodulin, a potential new obesity therapy and about the administration of peptides by oral inhalation using a simple, patient-friendly approach. |
|
|
|
Post by bobw on Jan 8, 2015 20:36:50 GMT -5
For what it is worth, my Norton anti-virus software is blocking the link that you posted, with the message "Suspicious Web Page Blocked".
|
|
|
|
Post by BD on Jan 8, 2015 20:47:04 GMT -5
For what it is worth, my Norton anti-virus software is blocking the link that you posted, with the message "Suspicious Web Page Blocked".
Dump Norton and get Kaspersky. |
|
|
|
Post by trenddiver on Jan 9, 2015 0:56:52 GMT -5
Also known as MKC 180. Mannkind has been investigating this hormone in connection with weight loss for at least 5 years. This is a perfect application for the Technosphere technology. MKC 180 was put on the back burner so the company's resources could be directed towards the success of Afrezza. Mannkind must be moving this up to the front burners now that Afrezza is on the launch pad with Sanofi. Billions are spent annually on weight loss. This could be the "next big thing" for Mannkind.
Trend
|
|
|
|
Post by biotec on Jan 9, 2015 7:35:25 GMT -5
Thats funny, At 1:50 Sanofi is presenting Targeting Diabetes Care through Weight Management
|
|
|
|
Post by notamnkdmillionaire on Jan 9, 2015 11:14:53 GMT -5
This info was posted a few months ago and I thank the OP for posting it again. This, imho, could be a very interesting development if this is the next technosphere target. But I would love to see MNKD unleash a few technosphere targets, weight loss and pain control.
|
|
|
|
Post by kc on Apr 25, 2015 10:45:58 GMT -5
What will we learn this week on this topic of Inhalation of Oxyntomodulin.
|
|
|
|
Post by joeypotsandpans on Apr 25, 2015 11:58:18 GMT -5
This may cause for concern for this gentleman: starcasm.net/archives/304624 ....is it me or does he have a bit of Al resemblance to him. On a more serious note, most people I know that have taken anything that had to go through the digestive tract when it came to weight loss items usually had/have the lower GI problems that come with it...I would imagine going pulmonary would totally avoid that which would be huge, let alone the speed factor again when those cravings come around  |
|
|
|
Post by Chris-C on Apr 25, 2015 12:54:45 GMT -5
Nice thread. This is a great lead. Does anyone remember if Hakan listed obesity as one of the primary Technosphere development targets in the last CC?
Thanks in advance,
Chris C
|
|
|
|
Post by sla55 on Apr 25, 2015 13:32:43 GMT -5
Hakan Edstrom: "Our current focus is on product in three areas pulmonary diseases, pain, and oncology support. As a relatively small company we cannot immediately begin working on several ambitious programs simultaneously. So as a practical matter you can expect us to begin full scale development activities on one target at a time, with each successive new target to be rolled out some months later. But importantly, we've already identified the area of development of the specific API and disease indication for each, and some key hires are also part of the plan."
|
|
|
|
Post by mannmade on Apr 25, 2015 16:43:53 GMT -5
If they pursue it then the Mybetes Food Naz_ tirade should be quelled as now you can have your "Afrezza" and eat too... To paraphrase a popular quote...
|
|
|
|
Post by mnholdem on Apr 25, 2015 19:45:12 GMT -5
Hakan did say that in MannKind would also be developing TS drugs for other companies' APIs in addition to the three areas where MannKind will be developing their own applications.
|
|
|
|
Post by jpg on Apr 25, 2015 20:14:48 GMT -5
My big question in all this is where do they get the money to do all these drug developments independently?
|
|
|
|
Post by xoxoxoxo on Apr 25, 2015 21:11:18 GMT -5
My big question in all this is where do they get the money to do all these drug developments independently? If only they'd announce some sort of deal where the other company pays all the R&D costs and we just end up getting a XX% royalty. |
|
